889 related articles for article (PubMed ID: 31057295)
1. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
2. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops.
Eibl G; Rozengurt E
Semin Cancer Biol; 2019 Feb; 54():50-62. PubMed ID: 29079305
[TBL] [Abstract][Full Text] [Related]
3. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
4. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis.
Morvaridi S; Dhall D; Greene MI; Pandol SJ; Wang Q
Sci Rep; 2015 Nov; 5():16759. PubMed ID: 26567630
[TBL] [Abstract][Full Text] [Related]
5. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice.
Hao F; Xu Q; Wang J; Yu S; Chang HH; Sinnett-Smith J; Eibl G; Rozengurt E
PLoS One; 2019; 14(5):e0216603. PubMed ID: 31100067
[TBL] [Abstract][Full Text] [Related]
6. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.
Zhang W; Nandakumar N; Shi Y; Manzano M; Smith A; Graham G; Gupta S; Vietsch EE; Laughlin SZ; Wadhwa M; Chetram M; Joshi M; Wang F; Kallakury B; Toretsky J; Wellstein A; Yi C
Sci Signal; 2014 May; 7(324):ra42. PubMed ID: 24803537
[TBL] [Abstract][Full Text] [Related]
7. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-Catenin
Gao C; Chen G; Zhang DH; Zhang J; Kuan SF; Hu W; Esni F; Gao X; Guan JL; Chu E; Hu J
Cell Mol Gastroenterol Hepatol; 2019; 8(4):561-578. PubMed ID: 31330317
[TBL] [Abstract][Full Text] [Related]
8. eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.
Strnadel J; Choi S; Fujimura K; Wang H; Zhang W; Wyse M; Wright T; Gross E; Peinado C; Park HW; Bui J; Kelber J; Bouvet M; Guan KL; Klemke RL
Cancer Res; 2017 Apr; 77(8):1997-2007. PubMed ID: 28381547
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
10. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
[TBL] [Abstract][Full Text] [Related]
11. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma.
Zhao C; Gong J; Bai Y; Yin T; Zhou M; Pan S; Liu Y; Gao Y; Zhang Z; Shi Y; Zhu F; Zhang H; Wang M; Qin R
Cell Death Differ; 2023 Jan; 30(1):1-15. PubMed ID: 35906484
[TBL] [Abstract][Full Text] [Related]
12. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
13. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
14. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma.
Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H
Front Oncol; 2021; 11():700315. PubMed ID: 34395269
[TBL] [Abstract][Full Text] [Related]
15. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
16. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
18. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
19. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C
Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622
[TBL] [Abstract][Full Text] [Related]
20. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
Wang MT; Fer N; Galeas J; Collisson EA; Kim SE; Sharib J; McCormick F
Nat Commun; 2019 Jul; 10(1):3055. PubMed ID: 31296870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
